Titan Pharmaceuticals

Titan Pharmaceuticals
Public
Traded as NASDAQ: TTNP
Industry Pharmaceuticals
Headquarters California
Number of employees
 14 (Dec 2016)
Website www.titanpharm.com

Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA developing proprietary therapeutics primarily for the treatment of central nervous system ("CNS") disorders.

Titan's principal asset is Probuphine,[1][2] a slow-release implant formulation of buprenorphine[3] for the treatment of opioid addiction or chronic pain. FDA Approval was granted on 26 May 2016.[4] It was licensed to Braeburn Pharmaceuticals for marketing and commercialization.[2]

References

  1. ↑ Probuphine®
  2. 1 2 http://ir.titanpharm.com/annual-reports#document-21870-0001144204-17-014986
  3. ↑ Solof, Barry (2013). The therapist's guide to addiction medicine a handbook for addiction counselors and therapists. New York: Central Recovery Press, LLC. p. 98. ISBN 9781937612443. Retrieved 21 September 2015.
  4. ↑ "Press Announcements - FDA approves first buprenorphine implant for treatment of opioid dependence". www.fda.gov. Retrieved 26 May 2016.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.